KRICT | PDE9A inhibitors

2017 한국화학연구원 신약R&D 산·연 기술교류회

KRICT 한국화학연구원

| Target | |
|---|---|
| Mechanism of Action | • Reversed cardiac dysfunction from TAC through PDE9A inhibition |
| Indication - Primary | • Hypertrophic heart disease (HFpEF) |
| Indication - Expansion | • Alzheimer's Dementia<br>• Sickle cell Disease |
| Route of Administration | • P.O. 24h after surgery (b.i.d.) |
| Competitive Advantage | • KR-3216682 and KR-3164701 were more effective than PF-0447943 (phase I) in various in vitro model such as PDE9A assay, cell based assay. |
| Data Files | • In vitro: Biochemical, Cell based PD, selectivity profile in subtype PDEs<br>• In vivo: TAC<br>• Physicohemical properties<br>• Metabolic stability, In vivo PK<br>• In vitro Toxicity (hERG, Cytotoxicity, CYP450) |
| IP Status | • Not yet |
| Collaboration Model | • Licensing for Global license or Selected territory<br>• Collaborative research project |
| Contact (Science) | • Kwang-Seok Oh (Biology, ksoh@krict.re.kr, +82-42-860-7547)<br>• Chae Jo Lim (Chemistry, chemlcj@krict,re,kr, +82-42-860-7154) |
| Contact (Licensing) | • Moon Geun Jung (Technology marketing office, mgjung@krict.re.kr, +82-42-860-7746)<br>• Choon-gil Kim (Technology marketing office, joykim@krict.re.kr, +82-42-860-7079)<br>• Kyung Sun Choi (Technology marketing office, chanian@krict.re.kr, +82-42-860-7076) |